Development of Nasal Vaccines and the Associated Challenges

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Oct 27

PMID 36297419

Authors

Xuanxuan Nian

Jiayou Zhang

Shihe Huang

Kai Duan

Xinguo Li

Xiaoming Yang

Affiliations

Soon will be listed here.

Abstract

Viruses, bacteria, fungi, and several other pathogenic microorganisms usually infect the host via the surface cells of respiratory mucosa. Nasal vaccination could provide a strong mucosal and systemic immunity to combat these infections. The intranasal route of vaccination offers the advantage of easy accessibility over the injection administration. Therefore, nasal immunization is considered a promising strategy for disease prevention, particularly in the case of infectious diseases of the respiratory system. The development of a nasal vaccine, particularly the strategies of adjuvant and antigens design and optimization, enabling rapid induction of protective mucosal and systemic responses against the disease. In recent times, the development of efficacious nasal vaccines with an adequate safety profile has progressed rapidly, with effective handling and overcoming of the challenges encountered during the process. In this context, the present report summarizes the most recent findings regarding the strategies used for developing nasal vaccines as an efficient alternative to conventional vaccines.

Citing Articles

Multifaceted virus-like particles: Navigating towards broadly effective influenza A virus vaccines.

Norizwan J, Tan W Curr Res Microb Sci. 2024; 8:100317.

PMID: 39717209 PMC: 11665419. DOI: 10.1016/j.crmicr.2024.100317.

Mannose and Lactobionic Acid in Nasal Vaccination: Enhancing Antigen Delivery via C-Type Lectin Receptors.

Colaco M, Cruz M, de Almeida L, Borges O Pharmaceutics. 2024; 16(10).

PMID: 39458637 PMC: 11510408. DOI: 10.3390/pharmaceutics16101308.

Acceptance of New Respiratory Syncytial Virus Vaccine among Pregnant Women in Nepal for Future Routine Immunization: A Descriptive Crosssectional Study.

Adhikari S, Chapagain R, Maharjan J, Kunwar K, Pudasaini S, Singh P JNMA J Nepal Med Assoc. 2024; 62(274):372-377.

PMID: 39356854 PMC: 11185303. DOI: 10.31729/jnma.8622.

Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges.

Bai Z, Wan D, Lan T, Hong W, Dong H, Wei Y ACS Nano. 2024; 18(36):24650-24681.

PMID: 39185745 PMC: 11394369. DOI: 10.1021/acsnano.3c10797.

Intranasal and intraperitoneal immunization against infection using niosome and mannosylated niosomes containing recombinant trigger factor/Bp26/Omp31 chimeric protein in a mouse model.

Sharif F, Nazari R, Fasihi-Ramandi M, Taheri R, Zargar M Clin Exp Vaccine Res. 2024; 13(3):232-241.

PMID: 39144123 PMC: 11319111. DOI: 10.7774/cevr.2024.13.3.232.

References

Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, Nomura T . Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J Virol. 2010; 84(24):12703-12. PMC: 3004317. DOI: 10.1128/JVI.01182-10. View

Date Y, Ebisawa M, Fukuda S, Shima H, Obata Y, Takahashi D . NALT M cells are important for immune induction for the common mucosal immune system. Int Immunol. 2017; 29(10):471-478. DOI: 10.1093/intimm/dxx064. View

Ramos M, Tak P, Lebre M . Fms-like tyrosine kinase 3 ligand-dependent dendritic cells in autoimmune inflammation. Autoimmun Rev. 2013; 13(2):117-24. DOI: 10.1016/j.autrev.2013.09.010. View

Andersen C, Dietrich J, Agger E, Lycke N, Lovgren K, Andersen P . The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun. 2006; 75(1):408-16. PMC: 1828435. DOI: 10.1128/IAI.01290-06. View

Xu H, Alzhrani R, Warnken Z, Thakkar S, Zeng M, Smyth H . Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration. Mol Pharm. 2020; 17(9):3259-3269. DOI: 10.1021/acs.molpharmaceut.0c00372. View

Hellfritzsch M, Scherliess R . Mucosal Vaccination via the Respiratory Tract. Pharmaceutics. 2019; 11(8). PMC: 6723941. DOI: 10.3390/pharmaceutics11080375. View

Durrani Z, McInerney T, McLain L, Jones T, Bellaby T, Brennan F . Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Methods. 1998; 220(1-2):93-103. DOI: 10.1016/s0022-1759(98)00145-8. View

Iwasaki A, Foxman E, Molony R . Early local immune defences in the respiratory tract. Nat Rev Immunol. 2016; 17(1):7-20. PMC: 5480291. DOI: 10.1038/nri.2016.117. View

Yamamoto M, Pascual D, Kiyono H . M cell-targeted mucosal vaccine strategies. Curr Top Microbiol Immunol. 2011; 354:39-52. PMC: 7393565. DOI: 10.1007/82_2011_134. View

10.

Kumar U, Afjei R, Ferrara K, Massoud T, Paulmurugan R . Gold-Nanostar-Chitosan-Mediated Delivery of SARS-CoV-2 DNA Vaccine for Respiratory Mucosal Immunization: Development and Proof-of-Principle. ACS Nano. 2021; 15(11):17582-17601. PMC: 8565460. DOI: 10.1021/acsnano.1c05002. View

11.

Sun W, Leist S, McCroskery S, Liu Y, Slamanig S, Oliva J . Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine. 2020; 62:103132. PMC: 7679520. DOI: 10.1016/j.ebiom.2020.103132. View

12.

Lin W, Griffin D, Rota P, Papania M, Cape S, Bennett D . Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci U S A. 2011; 108(7):2987-92. PMC: 3041112. DOI: 10.1073/pnas.1017334108. View

13.

Garg R, Brownlie R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S . A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3. Antiviral Res. 2018; 158:78-87. DOI: 10.1016/j.antiviral.2018.07.021. View

14.

Hu K, Lovgren-Bengtsson K, Morein B . Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev. 2001; 51(1-3):149-59. DOI: 10.1016/s0169-409x(01)00165-x. View

15.

DiNapoli J, Kotelkin A, Yang L, Elankumaran S, Murphy B, Samal S . Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A. 2007; 104(23):9788-93. PMC: 1887550. DOI: 10.1073/pnas.0703584104. View

16.

Erume J, Partidos C . Evaluation of the LTK63 adjuvant effect on cellular immune responses to measles virus nucleoprotein. Afr Health Sci. 2011; 11(2):151-7. PMC: 3158513. View

17.

Chaturvedi M, Kumar M, Pathak K . A review on mucoadhesive polymer used in nasal drug delivery system. J Adv Pharm Technol Res. 2012; 2(4):215-22. PMC: 3255357. DOI: 10.4103/2231-4040.90876. View

18.

Brandtzaeg P, Pabst R . Let's go mucosal: communication on slippery ground. Trends Immunol. 2004; 25(11):570-7. DOI: 10.1016/j.it.2004.09.005. View

19.

Carter N, Curran M . Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs. 2011; 71(12):1591-622. DOI: 10.2165/11206860-000000000-00000. View

20.

des Rieux A, Fievez V, Garinot M, Schneider Y, Preat V . Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006; 116(1):1-27. DOI: 10.1016/j.jconrel.2006.08.013. View